Trial Profile
A 24-week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Adult Subjects With Active Rheumatoid Arthritis on Stable Methotrexate Therapy With 104-Week Open Label Extension.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Decernotinib (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 16 Oct 2015 Results published in the Arthritis and Rheumatology
- 30 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 30 Oct 2013 Results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.